Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugs
- 1 December 2002
- journal article
- review article
- Published by Elsevier in American Journal Of Medicine
- Vol. 113 (9), 746-750
- https://doi.org/10.1016/s0002-9343(02)01363-3
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Grapefruit Juice Reduces the Oral Bioavailability of Fexofenadine But Not DesloratadineClinical Pharmacokinetics, 2002
- PharmacogeneticsClinical Pharmacokinetics, 2000
- IntroductionPharmacology, 2000
- Pharmacogenetics and psychopharmacotherapyJournal of Clinical Pharmacy & Therapeutics, 2000
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and FilipinosPharmacogenetics, 1995
- Genotype or phenotype: the definition of a pharmacogenetic polymorphismPharmacogenetics, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Variability in drug metabolism: importance of genetic constitutionInternational Journal of Clinical Pharmacy, 1987